Skip to content
DraconiticResearch
Search Sources API
194,216 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BY-NC-NDJournal of ovarian research

From cytoreduction to precision oncology: evolution of ovarian cancer therapy.

  • Ghassan M Saed1,2,3
  • Laura Detti4
  • Dina Massad5
  • Asma Basha5
  • Robert T Morris6
6 affiliations
  1. 1Department of Obstetrics and Gynecology, Wayne State University School of Medicine Karmanos Cancer Institute, Detroit, MI, 48201, USA. [email protected].
  2. 2Department of Gynecologic Oncology, Karmanos Cancer Institute, Detroit, MI, 48201, USA. [email protected].
  3. 3Department of Obstetrics and Gynecology, University of Jordan School of Medicine, 226 Queen Rania Al Abdulla St, Amman, 11942, Jordan. [email protected].
  4. 4Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA.
  5. 5Department of Obstetrics and Gynecology, University of Jordan School of Medicine, 226 Queen Rania Al Abdulla St, Amman, 11942, Jordan.
  6. 6Department of Gynecologic Oncology, Karmanos Cancer Institute, Detroit, MI, 48201, USA.
Read full textPDFDOICite

Abstract

Ovarian cancer remains the most lethal gynecologic malignancy due to its asymptomatic progression, limited screening modalities, and late-stage diagnosis. Although initial responses to platinum-based chemotherapy are common, recurrence and multidrug resistance are nearly universal, necessitating a shift toward biomarker-guided, precision-based interventions. This review synthesizes current evidence on the evolving landscape of ovarian cancer treatment, with emphasis on molecular pathogenesis, histotype-specific vulnerabilities, and advances in therapeutic strategies. Focus is placed on the clinical integration of poly (ADP-ribose) polymerase (PARP) inhibitors, vascular endothelial growth factor (VEGF)-targeting agents, immune checkpoint inhibitors, and antibody-drug conjugates, alongside emerging platforms such as liquid biopsy, artificial intelligence-enhanced diagnostics, and histotype-driven targeted therapies. Translational insights from other malignancies were utilized to highlight future directions for ovarian cancer, including dual pathway targeting, immune and epigenetic modulation, and receptor-guided cytotoxic delivery. Collectively, these advances demonstrate how precision oncology is advancing ovarian cancer treatment, with the potential to improve survival outcomes while preserving quality of life.

Related

  1. Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
    Yu Fujiwara, Shumei Kato, Razelle Kurzrock
    Hematology/Oncology Clinics of North AmericaPeer-reviewedLicence not stated20 citedOncologyOpenAlex
  2. Association of Complete Metabolic Response on Post-Neoadjuvant 18F-FDG PET/CT with Complete Cytoreduction in Advanced High-Grade Serous Tubo-Ovarian Carcinoma: A Retrospective Single-Center Cohort Study
    Basak Ozge Kayan, Ipek Ozturk, Yahya Ozgun Oner +7
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Bacterial Meningitis Following Robot-Assisted Radical Prostatectomy After Neoadjuvant Precision Oncology-Directed Therapy: A Case Report.
    Thomas Allen, Gabrielle R Yankelevich, Stephen J Savage +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Precision Cardio-Oncology: A Multimodal Approach to Cancer Therapy-Related Cardiovascular Toxicity Prediction and Assessment
    Carl Simela, Ishikaa Mukherjee, Abhinav Kandala +5
    CancersPeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMC
  5. Real-Time Biosensing of Cancer Therapy Response: Dynamic Biomarkers and the Shift Toward Feedback-Driven Precision Oncology
    Hannah Adeboye, Kwesi Akonu Adom Mensah Forson, Precious Esong Sone +2
    Journal of Cancer Biomoleculars and TherapeuticsPeer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{saed2026from,
  title = {{From cytoreduction to precision oncology: evolution of ovarian cancer therapy.}},
  author = {Ghassan M Saed and Laura Detti and Dina Massad and Asma Basha and Robert T Morris},
  journal = {Journal of ovarian research},
  year = {2026},
  month = jul,
  doi = {10.1186/s13048-026-02165-z},
  url = {https://europepmc.org/article/MED/42907928},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - From cytoreduction to precision oncology: evolution of ovarian cancer therapy.
AU  - Ghassan M Saed
AU  - Laura Detti
AU  - Dina Massad
AU  - Asma Basha
AU  - Robert T Morris
PY  - 2026
DA  - 2026/07/01
JO  - Journal of ovarian research
DO  - 10.1186/s13048-026-02165-z
UR  - https://europepmc.org/article/MED/42907928
AB  - Ovarian cancer remains the most lethal gynecologic malignancy due to its asymptomatic progression, limited screening modalities, and late-stage diagnosis. Although initial responses to platinum-based chemotherapy are common, recurrence and multidrug resistance are nearly universal, necessitating a shift toward biomarker-guided, precision-based interventions. This review synthesizes current evidence on the evolving landscape of ovarian cancer treatment, with emphasis on molecular pathogenesis, histotype-specific vulnerabilities, and advances in therapeutic strategies. Focus is placed on the clinical integration of poly (ADP-ribose) polymerase (PARP) inhibitors, vascular endothelial growth factor (VEGF)-targeting agents, immune checkpoint inhibitors, and antibody-drug conjugates, alongside emerging platforms such as liquid biopsy, artificial intelligence-enhanced diagnostics, and histotype-driven targeted therapies. Translational insights from other malignancies were utilized to highlight future directions for ovarian cancer, including dual pathway targeting, immune and epigenetic modulation, and receptor-guided cytotoxic delivery. Collectively, these advances demonstrate how precision oncology is advancing ovarian cancer treatment, with the potential to improve survival outcomes while preserving quality of life.
SN  - 1757-2215
ER  -